Date: December 6 – 8
Location: Edinburgh International Conference Centre
Our Senior Director • Business Development, Lynsey Haskayne, and Supervisor • ADQC / Inhalation Development, Fabio Russo, will attend DDL2023
Evotec excels in challenging oral inhalation and nasal product (OINDP) development, leveraging nanotechnology and therapeutic advantages. Our multidisciplinary teams drive inhaled product development for Phase I to late-stage clinical studies, offering tailored plans and robust strategies. Inhalation Analytics and Material Science ensure quality, supported by specific expertise and an integrated approach.
If you wish to discuss any inhalation development projects with Lynsey and Fabio, fill out the meeting form below or send an email to info@evotec.com
